{
    "organizations": [],
    "uuid": "04ccb3437dc931f43784b887083d58bc73df4868",
    "author": "",
    "url": "https://www.reuters.com/article/brief-luye-pharma-group-says-fda-to-waiv/brief-luye-pharma-group-says-fda-to-waive-pediatric-clinical-trials-of-schizophrenia-drug-idUSFWN1QB0IS",
    "ord_in_thread": 0,
    "title": "BRIEF-Luye Pharma Group Says FDA To Waive Pediatric Clinical Trials Of Schizophrenia Drug",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "February 21, 2018 / 2:46 PM / in 16 minutes BRIEF-Luye Pharma Group Says FDA To Waive Pediatric Clinical Trials Of Schizophrenia Drug Reuters Staff Feb 21 (Reuters) - Luye Pharma Group Ltd: * FDA AGREES TO WAIVE PEDIATRIC CLINICAL TRIALS OF SCHIZOPHRENIA DRUG LY03004 * FDAâ€˜S DECISION WILL SIGNIFICANTLY REDUCE RESEARCH AND DEVELOPMENT COST Source text for Eikon: Further company coverage:",
    "published": "2018-02-21T16:46:00.000+02:00",
    "crawled": "2018-02-21T17:03:36.029+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "february",
        "pm",
        "minute",
        "pharma",
        "group",
        "say",
        "fda",
        "waive",
        "pediatric",
        "clinical",
        "trial",
        "schizophrenia",
        "drug",
        "reuters",
        "staff",
        "feb",
        "reuters",
        "luye",
        "pharma",
        "group",
        "ltd",
        "fda",
        "agrees",
        "waive",
        "pediatric",
        "clinical",
        "trial",
        "schizophrenia",
        "drug",
        "ly03004",
        "fda",
        "decision",
        "significantly",
        "reduce",
        "research",
        "development",
        "cost",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}